STOCK TITAN

UroGen Pharma Ltd. Ordinary Shares - URGN STOCK NEWS

Welcome to our dedicated news page for UroGen Pharma Ltd. Ordinary Shares (Ticker: URGN), a resource for investors and traders seeking the latest updates and insights on UroGen Pharma Ltd. Ordinary Shares.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect UroGen Pharma Ltd. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of UroGen Pharma Ltd. Ordinary Shares's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.44%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
conferences
UroGen Pharma Ltd. Ordinary Shares

Nasdaq:URGN

URGN Rankings

URGN Stock Data

479.07M
24.37M
11.35%
70.5%
12.27%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
RA'ANANA

About URGN

urogen pharma ltd. (nasdaq:urgn) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. the company has developed rtgel™, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. urogen pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. urogen pharma's lead product candidates, mitogel™ (mitomycin urothelial gel) and vesigel™ (mitomycin intravesical gel), are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer, respectively. urogen pharma is headquartered in ra’anana, israel with u.s. headquarters in new york.